Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
Want to see VNDA full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.6Last Year’s EPS
-0.46Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a broadly positive commercial and pipeline momentum story: Fanapt demonstrated strong prescription growth and the company launched Nirius via a novel direct‑to‑consumer model while securing FDA approval for Dysanti and advancing imsidolimab toward potential year‑end regulatory action. Management raised 2026 revenue guidance and outlined multiple upcoming Phase 3 readouts that could be value drivers. Offsetting these positives are a materially larger Q1 net loss, increased operating expenses, a significant cash decline and ongoing Hetlioz erosion from generics, plus some development and recruitment risks for certain programs. Overall, commercial and regulatory catalysts appear to outweigh near‑term financial pressures.Company Guidance
Total Revenue Growth and Raised Guidance
Q1 2026 total net product sales were $51.7M, up 3% year-over-year (Q1 2025: $50.0M). Vanda raised full-year 2026 revenue guidance to $240M–$290M (midpoint $265M), implying ~23% revenue growth vs full-year 2025.
Fanapt Commercial Momentum
Fanapt Q1 2026 net product sales were $29.6M, up 26% year-over-year (Q1 2025: $23.5M). Prescription metrics: TRx +32% YoY and NBRx +76% YoY. Weekly TRx reached an eleven‑year high of >2.6k for week ending 04/24/2026. Full-year Fanapt guidance $150M–$170M (midpoint implies ~36% growth vs 2025).
Nirius U.S. Launch and Innovative DTC Model
Nirius launched nationwide via a direct-to-consumer platform (nirius.us) with a cash-pay offering. Company introduced 2026 Nirius revenue guidance of $10M–$30M. WAC price set at $255 per capsule with cash-pay discounted to $85 (~65%+ discount). Described as first new prescription therapy for prevention of motion‑induced vomiting in adults in >40 years.
Regulatory and Pipeline Progress — Dysanti Approval
Dysanti (milsoperidone) received FDA approval for bipolar I disorder and schizophrenia; protected by data exclusivity through 02/20/2031 and patents through 05/31/2044. Company expects Dysanti commercial availability in back half of 2026.
Imsidolimab Regulatory Milestone and Publication
FDA accepted the BLA for imsidolimab in generalized pustular psoriasis with a PDUFA target action date of 12/12/2026. Pivotal study results were published in NEJM Evidence (04/28/2026). Company is preparing commercial/regulatory activities in US, Europe, and Japan.
Late‑Stage Clinical Readouts Expected
Several key Phase 3 timelines: Dysanti adjunctive MDD readout expected Q1 2027, a Phase 3 study of Nirius for GLP‑1 induced vomiting expected in 2026, and Phase 3 VQW‑765 (social anxiety) results expected by 2026 — signaling multiple upcoming value‑creating catalysts.
Commercial Infrastructure Expansion
Fanapt sales force expanded from ~160 reps (end 2024) to ~300 reps (end 2025). Face‑to‑face calls in Q1 2026 were >80% higher vs Q1 2025, supporting continued prescription growth.
VNDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VNDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $7.44 | $6.39 | -14.11% |
Feb 11, 2026 | $7.43 | $6.12 | -17.63% |
Oct 29, 2025 | $5.41 | $4.32 | -20.15% |
Jul 31, 2025 | $4.67 | $4.26 | -8.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vanda Pharmaceuticals Inc. (VNDA) report earnings?
Vanda Pharmaceuticals Inc. (VNDA) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
What is Vanda Pharmaceuticals Inc. (VNDA) earnings time?
Vanda Pharmaceuticals Inc. (VNDA) earnings time is at Aug 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNDA EPS forecast?
VNDA EPS forecast for the fiscal quarter 2026 (Q2) is -0.6.